Teladoc and LifeMD to offer branded Zepbound vials through LillyDirect's pharmacy partner

Teladoc Health and LifeMD each announced on March 6, 2025 that they signed agreements with Gifthealth, the pharmacy partner behind Eli Lilly's LillyDirect, to give patients who pay without insurance access to branded Zepbound (tirzepatide) vials rather than compounded copies of the drug ^[1][2].

Under Teladoc's agreement, members enrolled in its Comprehensive Weight Care Program who lack insurance coverage for GLP-1s for obesity can have single-use Zepbound vials delivered to their homes if a Teladoc provider prescribes the drug for an on-label use ^[1]. Teladoc said its Comprehensive Weight Care and Primary360 teams will have full visibility into each stage of fulfillment, from dispensing to shipping to delivery to refills ^[1]. Teladoc said it does not offer compounded versions of the drugs, and that its patients are prescribed the branded medications ^[2].

LifeMD said its integration with LillyDirect's self-pay pharmacy channel would allow seamless access to branded Zepbound vials at what Reuters described as the newly reduced self-pay price ^[2]. LifeMD has offered access to compounded versions and "is prepared to respond appropriately to changes," the company said ^[2]. Neither announcement disclosed a dollar price or a specific start date for the integrations; Teladoc pointed members to LillyDirect for pricing information ^[1][2].

"At Teladoc Health, we are dedicated to expanding access to clinically responsible, evidence-based care," said Kelly Bliss, president of U.S. Group Health at Teladoc Health. "By integrating with LillyDirect, we are reducing barriers to high-quality care and helping our members afford transformative FDA-approved treatments while avoiding the potential risks of compounded medications recently offered by others" ^[1]. Robert Hoppe, executive vice president of life sciences at Gifthealth, said the integration aims to "remove barriers, improve medication access, and ensure that patients have reliable access to safe and effective weight management treatments" ^[1].

The agreements arrive as the market for compounded copies narrows. Zepbound and Novo Nordisk's Wegovy have been removed from the FDA's shortage list, and the FDA said in February there was no longer a shortage of Wegovy and Ozempic — a declaration Reuters reported would curtail widespread sales of cheaper copies ^[2]. A federal judge on Wednesday denied an injunction that would have allowed compounding pharmacies to keep making copies of Zepbound in the U.S. ^[2]. Citi analyst Daniel Grosslight said the Teladoc and LifeMD agreements suggest more deals of this kind are coming, given that bulk compounding is likely to be significantly curtailed ^[2]. Telehealth company Ro began offering single-dose vials of Zepbound in December and was already directly integrated with LillyDirect's self-pay pharmacy ^[2].

Why it matters for patients

For patients who pay cash for weight-loss medication, these deals show two of the larger telehealth platforms steering patients toward the branded, FDA-approved version of tirzepatide ^[1][2]. Teladoc framed the option as a way to avoid "the potential risks of compounded medications recently offered by others" ^[1]. The path is not open to everyone: Teladoc's self-pay option is aimed at members of its weight program who do not have GLP-1 coverage, and it requires a Teladoc clinician to prescribe Zepbound for an on-label indication ^[1]. What a patient pays will depend on LillyDirect's self-pay pricing, which was not stated in either announcement ^[1][2]. Whether compounding remains available at any given pharmacy is now subject to changing FDA shortage determinations and court rulings ^[2].

What happens next

Neither company disclosed when the integrations go live or how many patients they expect to reach ^[1][2]. The court ruling on compounded copies of Zepbound and the FDA's shortage decisions set the backdrop for how quickly telehealth companies shift from compounded to branded products ^[2].